Literature DB >> 21114431

Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS).

Noreen Hossain1, Maria Stepanova, Arian Afendy, Fatema Nader, Youssef Younossi, Nila Rafiq, Zachary Goodman, Zobair M Younossi.   

Abstract

BACKGROUND: Both non-alcoholic steatohepatitis (NASH) and polycystic ovary syndrome (PCOS) are associated with metabolic syndrome (MS) and insulin resistance (IR). Except for a few case reports, there are no systematic assessments of NASH in PCOS patients. AIM: To determine the prevalence of NASH and independent factors associated with NASH in a cohort of patients with documented PCOS.
METHODS: Patients with established diagnosis of PCOS and matched controls (matched for gender, age, and body mass index (BMI)) were included in the study. Causes of other liver diseases were systematically excluded by clinical and laboratory tests. Excessive alcohol use was defined as alcohol consumption of greater than 10 g/day. All liver biopsies were read by a single pathologist blinded to the clinical data. Histologic NASH was defined as steatosis with lobular inflammation and ballooning degeneration of hepatocytes with or without Mallory-Denk bodies or pericellular fibrosis. Univariate and multivariate analyses with logistic regression were performed to compare PCOS to matched controls.
RESULTS: Sixty-six patients were included in the study (34 PCOS and 32 matched controls). Of PCOS patients, 73% had a liver biopsy while 78% of the matched controls had a liver biopsy. In comparing PCOS patients to the matched controls, clinical (BMI, waist circumference, type 2 diabetes, MS, or its components, any alcohol consumption in the prior year, ethnic background, age, gender, etc.) and laboratory data (aminotransferases, ferritin, glucose, etc.) were not significantly different (p > 0.05). However, PCOS patients tended to have more histologic NASH on their liver biopsies (44.0% vs. 20.8%, p = 0.08). Independent predictors of histologic NASH in PCOS patients were elevated aspartate aminotransferase (AST), high triglycerides and small amounts of alcohol consumption (p = 0.019, 10-fold cross-validated AUC = 0.80, 95% CI = 0.56-0.94). Although about half of PCOS patients did not report any alcohol consumption, 50% did report rare alcohol use. In fact, PCOS patients with histologic NASH tended to report higher alcohol consumption per week than PCOS without NASH (3.80 ± 6.16 vs. 1.11 ± 1.87 g/week, p = 0.1). Nevertheless, these amounts of alcohol consumption were quite minimal.
CONCLUSIONS: Despite similar clinical and laboratory profiles to the matched controls, PCOS patients seem to have more histologic NASH. Although alcohol consumption was rare for both PCOS and controls, even rare alcohol consumption in PCOS patients was independently associated with histologic NASH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21114431     DOI: 10.3109/00365521.2010.539251

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  15 in total

Review 1.  Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.

Authors:  A L L Rocha; L C Faria; T C M Guimarães; G V Moreira; A L Cândido; C A Couto; F M Reis
Journal:  J Endocrinol Invest       Date:  2017-06-13       Impact factor: 4.256

Review 2.  Nonalcoholic fatty liver disease and polycystic ovary syndrome.

Authors:  Evangeline Vassilatou
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

3.  Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease.

Authors:  Alita Mishra; Zobair M Younossi
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

Review 4.  Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.

Authors:  Carly E Kelley; Ann J Brown; Anna Mae Diehl; Tracy L Setji
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 5.  Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?

Authors:  Giovanni Targher; Maurizio Rossini; Amedeo Lonardo
Journal:  Endocrine       Date:  2015-05-30       Impact factor: 3.633

Review 6.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

7.  Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis.

Authors:  Monika Sarkar; Norah Terrault; Wesley Chan; Marcelle I Cedars; Heather G Huddleston; Caroline C Duwaerts; Dana Balitzer; Ryan M Gill
Journal:  Liver Int       Date:  2019-11-12       Impact factor: 5.828

8.  The clinical characteristics and etiological study of nonalcoholic fatty liver disease in Chinese women with PCOS.

Authors:  Zhongyu Qu; Yanhui Zhu; Jingjing Jiang; Yuhua Shi; Zijiang Chen
Journal:  Iran J Reprod Med       Date:  2013-09

9.  Cannabinoid receptor 1 gene polymorphisms and nonalcoholic Fatty liver disease in women with polycystic ovary syndrome and in healthy controls.

Authors:  Justyna Kuliczkowska Plaksej; Lukasz Laczmanski; Andrzej Milewicz; A Lenarcik-Kabza; Anna Trzmiel-Bira; Urszula Zaleska-Dorobisz; Felicja Lwow; Lidia Hirnle
Journal:  Int J Endocrinol       Date:  2014-07-17       Impact factor: 3.257

10.  Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS).

Authors:  Ancha Baranova; Thuy Phuong Tran; Arian Afendy; Lei Wang; Amirhossein Shamsaddini; Rohini Mehta; Vikas Chandhoke; Aybike Birerdinc; Zobair M Younossi
Journal:  J Transl Med       Date:  2013-05-31       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.